Ideaya Biosciences Inc is a biotechnology company focused on the discovery and development of targeted therapeutics for the treatment of cancer
The company employs a precision medicine approach, leveraging its proprietary platform to identify and validate novel drug targets within various cancer types. By integrating advanced techniques in genomics and bioinformatics, Ideaya aims to create innovative therapies that specifically address the underlying genetic and molecular drivers of cancer, ultimately improving patient outcomes and extending survival. Its research pipeline includes a range of drug candidates currently in various stages of clinical development, demonstrating the company's commitment to advancing science and addressing unmet medical needs in oncology.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate.
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a favorable adverse event profile, highlighting IDE397's potential as a monotherapy.
